Peripheral Blood Stem Cell (PBSC) Collection Target Calculator
Calculates the target CD34+ cell collection dose required for autologous or allogeneic peripheral blood stem cell (PBSC) transplantation. Standard autologous HSCT target: 2-5 x 10^6 CD34+ cells/kg. Optimal target: 4-5 x 10^6 CD34+/kg. Minimum for engraftment: 2 x 10^6 CD34+/kg. Allogeneic: 4-8 x 10^6 CD34+/kg depending on centre protocol.
Score interpretation
Relatively low total cell collection target
→ Standard G-CSF mobilisation (filgrastim 10 mcg/kg/day for 4-5 days); monitor peripheral blood CD34+ count from day 4; apheresis when peripheral CD34+ count is 10/uL or above; single-day collection likely sufficient; aim for backup graft collection if possible; confirm collection adequacy with cell processing laboratory (CD34+ viability above 80%); cryopreserve in aliquots; document collection date, total volume, total CD34+ count, and viability in transplant records.
Moderate cell collection target -- may require 2 days of apheresis
→ G-CSF mobilisation with peripheral CD34+ monitoring from day 4; consider plerixafor (AMD3100) 0.24 mg/kg SC on evening of day 4 if peripheral CD34+ below 10-15/uL (poor mobiliser criteria); two-day apheresis may be required; coordinate with cell processing laboratory for daily CD34+ enumeration; ensure adequate venous access (peripheral or Hickman line); pre-apheresis calcium supplementation; monitor for PBSC mobilisation syndrome (splenomegaly, bone pain).
Large collection target -- multiple apheresis sessions likely required; senior review
→ Transplant physician and cell processing laboratory early planning; consider plerixafor prophylactically for poor mobilisers (prior treatment with melphalan, fludarabine, or lenalidomide); chemotherapy mobilisation (cyclophosphamide 2-4 g/m2 plus G-CSF) if steady-state mobilisation expected to be poor; multiple apheresis sessions planned; dedicated apheresis nursing team coordination; consider donor age, performance status, and comorbidities for allogeneic donors; ensure adequate cryopreservation capacity and liquid nitrogen storage for large volumes; document all procedures in national transplant registry (BSBMT/EBMT).
Interpretation bands for the PBSC Collection. Apply clinical judgement and local guidance.
References
- Mohty M, Ho AD. In and out of the niche: perspectives in mobilization of hematopoietic stem cells. Exp Hematol. 2011;39(5):467-475.
- FACT-JACIE International Standards for Hematopoietic Cellular Therapy. 7th Edition. 2018.
Related
Curated clinical cross-links plus same-class fallbacks.
- Oxycodone with naloxone · Strong opioid + peripheral opioid antagonist
- Sodium Cromoglicate Nasal Spray · Mast Cell Stabiliser — Allergic Rhinitis
- Olopatadine · H1 antihistamine + mast cell stabiliser
- Loperamide · Opioid Receptor Agonist (Peripheral — Antidiarrhoeal)
- Alendronic Acid (Alendronate) · Bisphosphonate (bone resorption inhibitor)
- Domperidone · Prokinetic Antiemetic (Peripheral Dopamine Antagonist)
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.